{
    "nct_id": "NCT05546476",
    "official_title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)",
    "inclusion_criteria": "* Documented active diagnosis of non-small cell lung, pancreatic, colorectal cancer\n* Cachexia defined by Fearon criteria of weight loss\n* Serum GDF-15 concentrations\n* Signed informed consent\n* ECOG PS â‰¤3 with life expectancy of at least 4 months to be able to complete Part A.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.\n* Current active reversible causes of decreased food intake.\n* Cachexia caused by other reasons.\n* History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody.\n* inadequate liver function\n* renal disease requiring dialysis",
    "miscellaneous_criteria": "Key"
}